These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39325652)

  • 1. Post-marketing safety of tralokinumab: a real-world pharmacovigilance study based on the FDA adverse event reporting system.
    Yang Z; Tang K; Chen J
    Expert Opin Drug Saf; 2024 Nov; 23(11):1439-1446. PubMed ID: 39325652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database.
    Yu M; Zhou L; Cao M; Ji C; Zheng Y
    Front Immunol; 2024; 15():1397692. PubMed ID: 39234238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Real-World Study on Adverse Reactions of Belimumab Based on the FDA Adverse Event Reporting System Database.
    Hai L; Wu J; Xie Y
    Pharmacoepidemiol Drug Saf; 2024 Oct; 33(10):e70037. PubMed ID: 39420647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.
    Li Y; Sun S; Wu H; Zhao L; Peng W
    BMC Pharmacol Toxicol; 2024 Sep; 25(1):71. PubMed ID: 39334280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of daratumumab in the real-world: a pharmacovigilance study based on FAERS database.
    Wu J; Wu H; Chen L; Liang H; Huang G; Yang S; Chen B; Noguchi Y; Shen Y
    Expert Opin Drug Saf; 2024 Jul; 23(7):905-916. PubMed ID: 38108285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database.
    Rong L; Xie M; Jiang M; Qiu H; Kong L
    Br J Clin Pharmacol; 2024 Aug; 90(8):1816-1826. PubMed ID: 36702463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System.
    Zhao D; Long X; Wang J
    Expert Opin Drug Saf; 2024 May; 23(5):599-605. PubMed ID: 38553867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disproportionality Analysis of Nusinersen in the Food and Drug Administration Adverse Event Reporting System: A Real-World Postmarketing Pharmacovigilance Assessment.
    Li Y; Zhang N; Jiang T; Gan L; Su H; Wu Y; Yang X; Xiang G; Ni R; Xu J; Li C; Liu Y
    Pediatr Neurol; 2024 Sep; 158():71-78. PubMed ID: 38981277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse Event Assessment of Upadacitinib: A Pharmacovigilance Study Based on the FAERS Database.
    Yuan J; Lu H; Zuo X; Yin L; Pu Y; Zhang J
    Pharmacoepidemiol Drug Saf; 2024 Oct; 33(10):e70030. PubMed ID: 39385705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang M; Cheng Q; Shi X; Sun MH
    Expert Opin Drug Saf; 2024 Mar; 23(3):353-362. PubMed ID: 37610085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab.
    Yun X; Zhou Y; Wu D; Liu Y; Wu Q
    Expert Opin Drug Saf; 2024 May; 23(5):581-591. PubMed ID: 38600747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-marketing safety concerns with rimegepant based on a pharmacovigilance study.
    Hu JL; Wu JY; Xu S; Qian SY; Jiang C; Zheng GQ
    J Headache Pain; 2024 Oct; 25(1):169. PubMed ID: 39375581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety Profile of Selective Serotonin Reuptake Inhibitors in Real-World Settings: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System.
    Zhao Y; Zhang Y; Yang L; Zhang K; Li S
    Ann Pharmacother; 2024 Nov; 58(11):1105-1116. PubMed ID: 38407147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database.
    Cui S; Li L; Liu W; Zhao B; Zhong X
    Braz J Med Biol Res; 2024; 57():e13392. PubMed ID: 39082578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance study.
    Chen M; Huang Y; Jiang S; Ke C
    Lung Cancer; 2024 Oct; 196():107966. PubMed ID: 39342769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacovigilance study of FDA adverse events for sugammadex.
    Mao X; Zhang R; Liang X; Liu F; Dai Y; Wang M; Huang H; Fu G
    J Clin Anesth; 2024 Oct; 97():111509. PubMed ID: 38880003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database.
    Yang Q; Wang J; Wang M; Zhang S; He QQ
    BMC Pharmacol Toxicol; 2024 Sep; 25(1):64. PubMed ID: 39267168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Data mining and safety analysis of avatrombopag: a retrospective pharmacovigilance study based on the US food and drug administration's adverse event reporting system.
    Zhu H; Wu M
    Sci Rep; 2024 May; 14(1):11262. PubMed ID: 38760419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
    Shu Y; Ding Y; Dai B; Zhang Q
    Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety evaluation of bempedoic acid: A pharmacovigilance analysis using FDA adverse event reporting system data.
    Li B; Zhang J; Huang A; Chen Y; Wei Q
    Int J Cardiol; 2024 Oct; 412():132305. PubMed ID: 38944350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.